The Rapid Rise of a Deadly Fungus Sparks Calls for Global Surveillance

1. A highly fatal, drug-resistant fungus, Candida auris, has proliferated globally, with cases increasing over 700% since the Covid-19 pandemic began, evolving into a major health threat.[para. 1]

2. A study led by Huang Guanghua from Fudan University, published April 22 in Clinical Microbiology Reviews, titled “Global Emergence and Rapid Spread of Candidozyma auris (syn. Candida auris): Epidemiology, Biology, and Antifungal Resistance,” examines its emergence, spread, and resistance from 2009 to 2025.[para. 2]

3. By December 2025, over 84,000 cases of colonization or infection were reported in 82 countries, surging from 14,244 in 2020 to 84,941 in 2025, posing a severe public health risk due to multidrug resistance.[para. 3]

4. The first recorded case was in Japan in 2009, isolated from a female patient's ear canal, named Candida auris accordingly.[para. 4]

5. C. auris causes superficial skin/mucosal infections and lethal bloodstream/deep organ infections; its drug resistance, transmissibility, and high bloodstream mortality rate label it a “superbug.”[para. 5]

6. It colonizes human skin and environments, causing outbreaks in healthcare settings via yeast or biofilms on skin/equipment; it resists antifungals and evades standard diagnostics, leading to high death rates.[para. 7]

7. Though first identified in 2009 Japan, retrospective analysis found a 1996 South Korea case; distinct clades emerged near-simultaneously in regions and spread.[para. 8]

8. Major outbreak waves: 2013-2016 with intercontinental spread; 2020-2022 overlapping Covid-19, fueled by vulnerable ICU patients, broad antibiotics, and corticosteroids.[para. 9]

9. The U.S. dominates with 65,321 cases (76.9% global total), due to superior diagnostics and surveillance.[para. 11]

10. Other high-burden countries (>1,000 cases): South Africa (2,670), UAE (2,281), China (2,150), Colombia (1,858), Spain (1,807), Saudi Arabia (1,730), Italy (1,198); 16 more (e.g., Greece, UK, India) have 100-1,000.[para. 12]

11. Low/middle-income countries report few/no cases due to diagnostic limitations.[para. 13]

12. Demographics: bimodal age (under 1 year: 14%; over 50: 55.3%); men comprise ~2/3 of cases.[para. 14]

13. Six genetic clades: Clade I (South Asia) 53.1%, Clade III (South Africa) 27.7%, Clade IV (South America) 14.8%.[para. 15]

14. CDC deems it an “urgent antimicrobial resistance threat”; WHO lists it as “critical priority” fungal pathogen in 2022.[para. 17]

15. Recommendations: enhance global diagnostics (esp. developing nations), build surveillance/infection controls (screening, disinfection, reporting), develop affordable diagnostics/new antifungals, and foster international cooperation.[para. 18][para. 19]

(Word count: 498)